These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 1850647)

  • 1. [Clinical significance of measuring serum c-peptide before and after glucagon injection].
    Kan Y; Chi Z
    Zhonghua Yi Xue Za Zhi; 1991 Jan; 71(1):16-7, 4. PubMed ID: 1850647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical usefulness of the glucagon test in the study of pancreatic islet cell function].
    Llorente I; Goñi MJ; Forga L; Monreal M; Lizcano F; Moncada E
    Rev Med Univ Navarra; 1992; 37(1):25-9. PubMed ID: 1626165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of glucagon on plasma ghrelin level in type 2 diabetes mellitus].
    Lin SD; Chen ZX; Lin CJ; Duan HY
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(14):967-9. PubMed ID: 19671308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [C-peptide levels in secondary sulfonylurea resistant diabetics].
    Balázsi I; Takács J; Hargitai G
    Orv Hetil; 1993 Dec; 134(52):2859-62. PubMed ID: 8272351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The diagnostic value of serum C-peptide determination].
    Kober G; Rainer OH
    Acta Med Austriaca; 1983; 10(2-3):67-70. PubMed ID: 6349209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [C-peptide as the decisive factor for classification of type 1 diabetes mellitus and type 2 diabetes mellitus].
    Perusicová J; Bárová H; Hill M; Masek Z
    Vnitr Lek; 2002 Jun; 48(6):490-9. PubMed ID: 12132349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics in the discrimination between patients with low or high C-peptide level among middle-aged insulin-treated diabetics.
    Laakso M; Sarlund H; Pyörälä K
    Diabetes Res; 1987 Feb; 4(2):95-9. PubMed ID: 3581663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [C-peptide determination in diabetics for the evaluation of insulin requirements].
    Keller U; Pasquel M; Berger W
    Schweiz Med Wochenschr; 1987 Feb; 117(6):187-92. PubMed ID: 3551060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretory protein 7B2 response to oral glucose loading and intravenous glucagon injection in patients with diabetes mellitus.
    Hisatomi A; Natori S; Iguchi H; Ohashi M; Umeda F; Nawata H
    Fukuoka Igaku Zasshi; 1996 Dec; 87(12):266-73. PubMed ID: 9011109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C-peptide response to glucagon injections in IDDM and NIDDM patients.
    Poulsen S; Billesbølle P; Kølendorf K; Thorsteinsson B
    Horm Metab Res; 1985 Jan; 17(1):39-40. PubMed ID: 3967844
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.
    Albareda M; Rigla M; Rodríguez-Espinosa J; Caballero A; Chico A; Cabezas R; Carreras G; Pérez A
    Diabetes Res Clin Pract; 2005 Jun; 68(3):202-6. PubMed ID: 15936461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.
    Iwasaki Y; Kondo K; Hasegawa H; Oiso Y
    Diabetes Res; 1994; 25(3):129-37. PubMed ID: 7671552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes.
    Goel A; Chiu H; Felton J; Palmer JP; Brooks-Worrell B
    Diabetes; 2007 Aug; 56(8):2110-5. PubMed ID: 17473222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum C-peptide after 6 months on glibenclamide remains higher than during insulin treatment.
    Peacock I; Watts R; Selby C; Tattersall RB
    Diabetes Res; 1987 Oct; 6(2):57-9. PubMed ID: 3123115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-induced plasma C-peptide response in diabetic patients. Influence of body weight and relationship to insulin requirement.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Diabetes Metab; 1996 Dec; 22(6):455-8. PubMed ID: 8985655
    [No Abstract]   [Full Text] [Related]  

  • 16. Circadian variations in plasma immunoreactive insulin (IRI) and C-peptide concentrations in adult onset (type II) diabetes mellitus.
    Nicolau GY; Haus E; Lakatua DJ; Bogdan C; Petrescu E; Sackett-Lundeen L; Stelea S; Stelea P
    Endocrinologie; 1984; 22(1):3-16. PubMed ID: 6369501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-peptide pattern in patients with pancreatic cancer.
    Fogar P; Basso D; Panozzo MP; Del Favero G; Briani G; Fabris C; D'Angeli F; Meggiato T; Ferrara C; Plebani M
    Anticancer Res; 1993; 13(6B):2577-80. PubMed ID: 8135497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of beta cell function in non-insulin-dependent diabetes mellitus (NIDDM) and its correlations with clinico-metabolic parameters].
    Santoro E; Gianni R; Maggi L; Tomassini CR; Bisacchi U
    G Clin Med; 1989 Feb; 70(2):95-9. PubMed ID: 2666224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-peptide response to glucagon in diabetics with and without complications.
    Smith RB; Pyke DA; Watkins PJ; Binder C; Faber OK
    N Z Med J; 1979 Apr; 89(634):304-6. PubMed ID: 377156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of the radioimmunological determination of C-peptide (author's transl)].
    Dudczak R; Waldhäusl W
    Wien Klin Wochenschr; 1979 Oct; 91(19):658-62. PubMed ID: 120077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.